Valuation: Altimmune Inc

Market Cap 556M 490M 464M 419M 790M 53.34B 800M 5.55B 2.14B 27.27B 2.09B 2.04B 87.43B P/E 2026 *
-4.91x
P/E 2027 * -4.5x
Enterprise Value 116M 102M 96.63M 87.24M 164M 11.11B 167M 1.16B 445M 5.68B 435M 425M 18.2B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-1.88%-4.03%+29.52%+36.14% 44.25B
+2.32%+4.69%+356.26%+699.54% 43.99B
-1.02%+0.83%+8.29%+103.33% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.15%-9.54%-25.35%+333.39% 24.93B
Average +0.61%+1.97%+55.35%+161.57% 44.09B
Weighted average by Cap. +0.74%+1.83%+59.61%+152.79%

Financials

2026 *2027 *
Net sales - -
Net income -99.55M -87.66M -83.06M -74.98M -141M -9.54B -143M -994M -382M -4.88B -374M -366M -15.64B -117M -103M -97.43M -87.96M -166M -11.2B -168M -1.17B -449M -5.72B -438M -429M -18.35B
Net Debt -440M -388M -368M -332M -625M -42.24B -633M -4.4B -1.69B -21.59B -1.65B -1.62B -69.23B -332M -292M -277M -250M -471M -31.8B -477M -3.31B -1.27B -16.26B -1.25B -1.22B -52.13B
Logo Altimmune Inc
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-